Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 218 of 6351
-
Can a new electric pulse technique tame Post-Heart-Attack heart rhythms faster?
Disease control Recruiting nowASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE…
Sponsor: Pasquale Santangeli • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink inoperable bile duct tumors?
Disease control OngoingQL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors:A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Phase 2 • Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New obesity drug shows promise in major japanese trial
Disease control OngoingThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a diabetes drug protect obese Teens' hearts?
Disease control Recruiting nowThe goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index …
Sponsor: John Bauer • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
A simple blood test might spot sepsis risk before symptoms worsen
Diagnosis Stopped earlyThis study will establish the clinical performance of the Monocyte Distribution Width (MDW) parameter on the DxH 900/ DxH 690T hematology analyzers to aid in the detection and risk assessment of patients in the Emergency Department (ED) for progression to sepsis.
Sponsor: Beckman Coulter, Inc. • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Could a single daily pill slash heart disease risks?
Disease control Recruiting nowThe EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a max…
Phase 3 • Sponsor: Hospital do Coracao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for bipolar mania? phase 3 trial of KarXT begins
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Blood test may predict who needs less immunotherapy after lung cancer surgery
Diagnosis Recruiting nowThe purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can he…
Phase 2 • Sponsor: University of Miami • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThe study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or …
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for schizophrenia: KarXT enters Late-Stage trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New combo aims to cure hepatitis b without lifelong pills
Disease control Recruiting nowThis is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
Phase 2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a single injection drug calm the immune attack on kidneys?
Disease control OngoingThis study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients an…
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a…
Phase 2/3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
Prevention Recruiting nowFollowing on the heels of large implementation science projects that participated in the launch of widespread daily oral PrEP availability, investigators will launch and study the integration of novel PrEP products - beginning with the dapivirine ring- into existing PrEP programs…
Phase 4 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail aims to stop bile duct cancer recurrence
Disease control Recruiting nowThis study is designed as a prospective, randomized, open-label, phase II clinical trial to systematically evaluate the efficacy and safety of durvalumab combined with GEMOX/GC chemotherapy followed by lenvatinib, compared with capecitabine monotherapy, as adjuvant therapy for bi…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a Patient's own blood plasma kickstart ovulation in PCOS?
Disease control CompletedThe goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian respon…
Sponsor: Bangladesh Medical University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can Open-Heart surgery outperform a Tube-Based valve fix?
Disease control Recruiting nowTo establish the safety and effectiveness of surgical aortic valve replacement (SAVR) in patients with isolated severe, calcific aortic stenosis who are at low surgical risk.
Sponsor: Osaka University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Stroke treatment window could expand to 72 hours in new trial
Disease control Recruiting nowThe benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg…
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for melanoma brain metastases: Two-Step treatment trial launches
Disease control Recruiting nowBrain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urg…
Phase 2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for blood cancer patients: experimental drug BGB-16673 enters phase 3 trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chron…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC